Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia

Anemia of chronic kidney disease (CKD) can be corrected by treatment with recombinant human erythropoietin (rHuEPO); however, some patients become hyporesponsive. The molecular mechanisms underlying this resistance remain to be elucidated. Our aim was to study hyporesponsiveness to rHuEPO therapy us...

Full description

Bibliographic Details
Main Author: Ribeiro, Sandra (author)
Other Authors: Garrido, Patrícia (author), Fernandes, João (author), Vala, Helena (author), Rocha-Pereira, Petronila (author), Costa, Elísio (author), Belo, Luís (author), Reis, Flávio (author), Santos-Silva, Alice (author)
Format: article
Language:eng
Published: 2016
Subjects:
Anemia
TGF-b1
CTGF
Erythropoietin
Hyporesponsiveness
Inflammation
Online Access:http://hdl.handle.net/10400.19/3156
Country:Portugal
Oai:oai:repositorio.ipv.pt:10400.19/3156

Internet

http://hdl.handle.net/10400.19/3156

Similar Items